Serum concentrations of high-sensitivity C-reactive protein predict progressively obstructive lesions rather than late restenosis in patients with unstable angina undergoing coronary artery stenting

Circulation Journal

Volumn 69, Issue 10, 2005, Pages 1202-1207

  Yip, Hon Kan ^a   Hung, Wei Chin ^a   Yang, Cheng Hsu ^a   Chen, Yen Hsun ^a   Cheng, Cheng I ^a   Chen, Shyh Ming ^a   Yeh, Kuo Ho ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

C reactive protein; Coronary angioplasty; Unstable angina

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; C REACTIVE PROTEIN; CLOPIDOGREL; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SIMVASTATIN; THALLIUM 201;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DISEASE COURSE; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HYPERCHOLESTEROLEMIA; IN-STENT RESTENOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

AGED; ANGINA, UNSTABLE; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; CORONARY RESTENOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; STENTS;

EID: 25644446050     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.69.1202     Document Type: Article

References (26)

1. Ross R. The pathogenesis of atherosclerosis: A perspective for 1990s. Nature 1993; 362: 801-809.
2. Pasceri V, Chang J, Willerson JT, Yeh ETH. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cell by anti-atherosclerosis drugs. Circulation 2001; 103: 2531-2534.
3. Verma S, Buchanan MR, Anderson TJ. Endothelial function testing as a biomarker of vascular disease. Circulation 2003; 108: 2054-2059.
4. Szmitko PE, Wang CH, Weisel RD, de Almeida JR, Anderson TJ, Verma S. New makers of inflammation and endotheial cell activation: Part I. Circulation 2003; 108: 1917-1923.
5. Koenig W, Sund M, Frohlich M, Fischer HG, Lowel H, Doring A, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99: 237-242.
6. Rider PM. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-1818.
7. Mueller C, Buettner HJ, Hodgson JM, Marsch S, Perruchoud AP, Roskamm H, et al. Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation 2002; 105: 1412-1415.
8. Yip HK, Hang CL, Fang CY, Hsieh YK, Yang CH, Hung WC, et al. Level of high-sensitivity C-reactive protein is predictive of 30-day outcomes in patients with acute myocardial infarction undergoing primary coronary intervention. Chest 2005; 127: 803-808.
9. Morrone G, Ciliberto G, Oliviero S, Arcone R, Dente L, Content J, et al. Recombinant interleukin 6 regulates the transcriptional activation of a set of human acute phase genes. J Biol Chem 1988; 263: 12554-12558.
10. Le J, Vilcek J. Interleukin 6: A multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588-602.
11. Rider PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342: 836-843.
12. Hermiller JB, Cusma JT, Spero LA, Fortin DF, Harding MB, Bashore TM. Quantitative and qualitative coronary angiographic analysis: Review of methods, utility, and limitations. Cathet Cardiovasc Diagn 1992; 25: 110-131.
13. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. Circulation 1994; 89: 36-44.
14. Yeung AC, Tsao P. Statin therapy: Beyond cholesterol lowering and anti-inflammatory effects. Circulation 2002; 105: 2937-2938.
15. van de Ree MA, Huisman MV, Princen HMG, Meinders AE, Kluft C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-135.
16. Kinlay S, Selwyn AP. Effect of statins on inflammation in patients with acute and chronic coronary syndromes. Am J Cardiol 2003; 91(suppl): 9B-13B.
17. Choi H, Cho DH, Shin HH, Park JB. Association of high sensitivity C-reactive protein with coronary heart disease prediction, but not with carotid atherosclerosis, in patients with hypertension. Circ J 2004; 68: 297-303.
18. Lim SY, Jeong MH, Bae EH, Kim W, Kim JH, Hong YJ, et al. Predictive factors of major adverse cardiac events in acute myocardial infarction patients complicated by cardiogenic shock undergoing primary percutaneous coronary intervention. Circ J 2005; 69: 154-158.
19. Buffon A, Liuzzo G, Biasucci LM, Pasqualetti P, Ramazzotti V, Rebuzzi AG, et al. Preprocedural serum levels of C-Reactive protein predict early complications and late restenosis after coronary angioplasty. J Am Coll Cardiol 1999; 34: 1512-1521.
20. Walter DH, Fichtlscherer S, Sellwig M, Auch-Schwelk W, Schachinger V, Zeiher AM. Preprocedural serum C-reactive protein levels and cardiovascular events after coronary stent implantation. J Am Coll Cardiol 2001; 37: 839-846.
21. Cipollone F, Ferri C, Desideri G, Paloscia L, Materazzo G, Mascellanti M, et al. Preprocedural level of soluble CD40L is predictive of enhanced inflammatory response and restenosis after coronary angioplasty. Circulation 2003; 108: 2776-2782.
22. Zhou YF, Csako G, Grayston JT, Wang SP, Yu ZX, Shou M, et al. Lack of association of restenosis following coronary angioplasty with elevated C-reactive protein levels or seropositivity to Chlamydia pneumoniae. Am J Cardiol 1999; 84: 595-598.
23. Dibra A, Mehilli J, Braun S, Hadamitzky M, Baum H, Dirschinger J, et al. Association between C-reactive protein levels and subsequent cardiac events among patients with stable angina treated with coronary artery stenting. Am J Med 2003; 114: 715-722.
24. Imai K, Matsubara T, Kanashiro M, Ichimiya S, Hotta N. Lipid peroxidation may predict restenosis after coronary balloon angioplasty. Jpn Circ J 2001; 65: 495-499.
25. Gomez-Gerique JA, Ros E, Olivan J, Mostaza JM, Vilardell M, Pinto X, et al. Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis 2002; 162: 245-251.
26. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al. Cardiovascular morbidity in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.